Founders & CXOs

Dr Suchitra K Ella — Co-Founder of Bharat Biotech — Has Been Named CII President-Designate for 2026-27. A Healthcare Leader at the Head of Indian Industry.

By Mustafa Shariff, Editor in Chief · May 20, 2026 · 2 min read

Summary

• Dr Suchitra K Ella Named CII President-Designate 2026-27: A Healthcare Leader Steps Into India's Industrial Leadership
• Dr Suchitra K Ella, co-founder of Bharat Biotech, has been named CII President-Designate for 2026-27. Here is the full significance of this appointment for India's healthcare and industrial leadership.

"Dr Suchitra Ella's appointment as CII President-Designate reflects the growing recognition that healthcare and life sciences are not peripheral to India's industrial story — they are central to it. Bharat Biotech's Covaxin, the R21 malaria vaccine supply, and two decades of vaccine innovation for the world's most vulnerable populations speak for themselves."

The Confederation of Indian Industry elected its new office bearers for 2026-27 on May 12, 2026, at the newly constituted National Council meeting. The appointments are significant — and one in particular carries specific significance for India's healthcare and life sciences sector. Dr Suchitra K Ella, Co-Founder and Managing Director of Bharat Biotech International Limited, has been appointed CII President-Designate for 2026-27. She takes the position alongside R Mukundan, Managing Director and CEO of Tata Chemicals, who assumes the CII Presidency for 2026-27.

Dr Suchitra Ella's biography is inseparable from India's vaccine story of the past three decades. She co-founded Bharat Biotech International in 1996 — alongside her husband Dr Krishna Ella — at a time when India's private vaccine manufacturing sector was nascent and the idea that an Indian company could develop indigenous vaccines for global markets was largely theoretical. Over the following decades, Bharat Biotech built a reputation for tackling the vaccines that others could not or would not make: rotavirus, typhoid conjugate, Hib pentavalent, rabies, and eventually the COVID-19 pandemic.

What Dr Ella Has Built

Covaxin — India's first indigenously developed COVID-19 vaccine, produced entirely in India using a whole-virion inactivated vero cell platform — was Bharat Biotech's most prominent global moment. Developed in an extraordinary timeline and approved for emergency use by the DCGI in January 2021, Covaxin became one of the two vaccines that drove India's national COVID-19 immunisation programme — the largest vaccination campaign in history. The vaccine was subsequently granted Emergency Use Listing by WHO, exported to multiple countries, and became a point of national scientific pride for India's indigenous biopharmaceutical capabilities.

Beyond COVID, Dr Suchitra has co-founded and nurtured several companies in adjacent life sciences categories — veterinary sciences, agri-biotech parks, food processing, and pre-clinical toxicology and research institutes — demonstrating an entrepreneurial range that extends well beyond traditional pharmaceutical manufacturing. In 2022, she was honoured with the Padma Bhushan — one of India's highest civilian awards — for her outstanding contributions to industry and society.

What the CII President-Designate Role Means

The CII President-Designate serves for one year before ascending to the CII Presidency the following year. The role involves representing India's largest industry body — which encompasses 9,000+ member companies across 60 sectors — in dialogues with government, international trade bodies, and policy forums. The CII President and President-Designate are the industry body's most visible public voices on issues ranging from economic policy and trade negotiations to regulatory frameworks and industrial development.

The appointment of a healthcare and life sciences leader as CII President-Designate is significant because the CII has historically been led by executives from manufacturing, chemicals, infrastructure, and technology sectors. Dr Ella's appointment reflects a structural shift: healthcare and life sciences — which now contribute over $130 billion to India's economy through pharmaceutical exports, hospital services, and medical devices — are no longer peripheral to India's industrial story. They are central to it.

The Healthcare Policy Implications

Dr Ella's CII President-Designate position will give the healthcare and life sciences sector a more prominent voice in the industry's engagements with government on economic policy, regulatory reform, and international trade negotiations. Specific healthcare policy areas where CII advocacy can be particularly impactful include Biopharma SHAKTI implementation, intellectual property policy as India navigates the balance between generic access and innovation incentives, India-US and India-UK trade negotiations where pharmaceutical provisions are significant, CDSCO regulatory reform, and the startup ecosystem enabling environment for healthcare innovation.

BHC Perspective

At Bengaluru Health Community, Dr Suchitra Ella's appointment as CII President-Designate is a landmark moment for India's healthcare and life sciences leadership. She represents exactly what BHC's Mentorship Platform is built to foster: a healthcare entrepreneur who built something globally significant — Covaxin, a WHO-listed vaccine — from a platform in India. For BHC mentors and mentees alike, Dr Ella's career is the definition of what healthcare entrepreneurship from India can achieve.

Frequently Asked Questions

Q: Who is Dr Suchitra K Ella?
A: Co-Founder and Managing Director of Bharat Biotech International Limited, co-developer of Covaxin (India's indigenous COVID-19 vaccine), Padma Bhushan awardee 2022, founder of multiple companies in veterinary sciences, agri-biotech, and food processing.

Q: What is the CII President-Designate role?
A: CII President-Designate serves for one year before ascending to the CII Presidency the following year — representing the Confederation of Indian Industry (9,000+ member companies, 60 sectors) in dialogues with government, international trade bodies, and policy forums.

Q: Why is this appointment significant for healthcare?
A: It is the first time a healthcare and life sciences leader of Dr Ella's stature has been named CII President-Designate — reflecting the structural shift that has made healthcare and life sciences (₹130 billion+ contribution to India's economy) central rather than peripheral to India's industrial leadership conversation.